Medistim uses cookies to improve your experience on our website. Read more about our Cookie Policy here Dismiss MENU Font size tip Results for the Second Quarter and First Half 2021 Posted on 13. August 2021 by Benedicte Meydel Total revenues for the quarter ended at MNOK 109.8 (MNOK 82.5) and includes MNOK 5.3 granted by the U.S. Paycheck Protection Program related to COVID-19. Total revenues for the first half ended at MNOK 212.4 (185.6). Operating profit (EBIT) for the quarter ended at MNOK 42.7 (MNOK 27.7), a 54.0% increase and by far the best EBIT for a quarter ever. Operating profit for the first half ended at MNOK 71.7 (MNOK 52.5), a 36.7% increase. This is also the best operating profit for the first half ever. High growth in number of procedures in the USA with 50% – as well as consumable probe sales growth with 35% – reflect an increasing number of surgeries being performed and continuing recovery from the COVID pandemic. See the full presentation and report below. Q2 and 1st half report 2021 presentation Q2 and 1st half report 2021 Products MIRAQ CARDIAC MIRAQ VASCULAR MIRAQ ULTIMATE IMAGING PROBE FLOW PROBES Clinical CARDIAC SURGERY TRANSPLANT SURGERY VASCULAR SURGERY AV ACCESS SURGERY PERIPHERAL BYPASS SURGERY CAROTID ENDARTERECTOMY SURGERY Technology TECHNOLOGY TRANSIT TIME FLOW MEASUREMENT ULTRASOUND IMAGING DOPPLER VELOCITY Medistim ABOUT MEDISTIM PERSONAL DATA PROTECTION POLICY OUR HISTORY MANAGEMENT TEAM CERTIFICATES NEWS INVESTOR RELATIONS OUR DISTRIBUTORS CONTENT PORTAL EDUCATION EVENTS Built with WordPress